Zenith Capital (Zenith Capital) Cash Flow for Lease Financing : $ Mil (TTM As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Cash Flow for Lease Financing?

Zenith Capital's Cash Flow for Lease Financing for the three months ended in . 20 was $0.00 Mil. Zenith Capital does not have enough years/quarters to calculate the Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in . 20.

Compared with last quarter ($0.00 Mil in . 20 ), Zenith Capital's Cash Flow for Lease Financing remained the same in . 20 ($0.00 Mil).

Zenith Capital Cash Flow for Lease Financing Historical Data

The historical data trend for Zenith Capital's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Cash Flow for Lease Financing Chart

Zenith Capital Annual Data

Trend

Cash Flow for Lease Financing

Zenith Capital Quarterly Data

Cash Flow for Lease Financing

Zenith Capital Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.

Zenith Capital Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Cash Flow for Lease Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines